4. Non-Hormonal and Adjunctive Therapies
Pedagogy: This lesson uses intervention-matching — linking psychological therapy options to specific symptom profiles and identifying which patients will benefit most from CBT vs pharmacotherapy.
Learning Objectives
- Describe the evidence base for menopause-specific CBT from NICE NG23
- Identify the three symptom domains where CBT is most effective: VMS, sleep, and low mood
- Explain when to offer CBT alongside, instead of, or in addition to HRT
- Acknowledge access limitations and self-help alternatives
Key Facts
Menopause-Specific CBT
NICE NG23 (2024) recommends menopause-specific CBT for: VMS, difficulties with sleep, or low mood — either in addition to HRT, for those in whom HRT is contraindicated, or for those who prefer non-pharmacological treatment. High-quality evidence from multiple RCTs supports its effectiveness (1).
CBT reduces the impact of VMS (how much they bother the woman) rather than their frequency. It also improves sleep quality and mood. It can be delivered face-to-face, by telephone, or via guided self-help workbooks.
When to Offer CBT
| Scenario | CBT Role |
|---|---|
| Alongside HRT | For women with residual VMS impact, sleep problems, or mood symptoms despite adequate HRT |
| Instead of HRT | When HRT is contraindicated (e.g. breast cancer) or declined |
| For specific symptoms | CBT-I (insomnia-specific) is the first-line treatment for chronic insomnia, including menopause-related |
Access Limitations
NHS waiting lists for psychological therapy are long. Guided self-help workbooks (e.g. 'Managing Hot Flushes and Night Sweats' by Myra Hunter) provide an accessible alternative. Online CBT platforms are emerging. The IMS 2025 acknowledges that access remains a significant barrier (2).
Clinical Pearl CBT does not reduce the NUMBER of hot flushes — it reduces their IMPACT on quality of life. This distinction matters when counselling patients about what to expect.
Clinical Pearl CBT-I (CBT for insomnia) is the first-line treatment for chronic insomnia in guidelines worldwide — including menopause-related insomnia. It is more effective long-term than pharmacotherapy.
Case-Based Examples
Case 1: 52-year-old with VMS well-controlled on HRT but persistent poor sleep
Presentation: A 52-year-old on adequate HRT reports VMS are well-controlled but she still wakes at 3am and cannot return to sleep. She has tried over-the-counter melatonin without benefit.
Question: What would you recommend?
Model Answer: Her insomnia may be independent of VMS (common in perimenopause). CBT-I is first-line for chronic insomnia (NICE, AASM). Refer via IAPT/NHS Talking Therapies for CBT-I if available. In the interim, recommend self-help resources (e.g. Sleepio app, NHS CBT-I guides). Sleep hygiene counselling: consistent wake time, avoid screens before bed, no caffeine after 2pm. Melatonin has limited evidence for menopause-related insomnia. Hypnotics (zopiclone) are not recommended long-term.
Case 2: Breast cancer survivor declining all pharmacological treatment
Presentation: A 55-year-old breast cancer survivor (ER+) declines fezolinetant due to liver function concerns and declines all other medication. She has moderate VMS and low mood.
Question: Design a non-pharmacological management plan.
Model Answer: Menopause-specific CBT: address both VMS impact and low mood (NICE NG23 recommended). Refer via IAPT/NHS Talking Therapies specifying menopause-specific CBT. Self-help: guided workbook by Myra Hunter. Lifestyle: regular exercise (150 min/week — evidence for mood, VMS, and sleep benefit), weight management, mindfulness-based stress reduction (emerging evidence). Cool clothing, bedroom temperature management, layered dressing. Support group referral (e.g. Macmillan, Breast Cancer Now menopause support). Review in 3 months — she may reconsider pharmacological options once non-pharmacological strategies are in place.
Self-Assessment Questions
PLAB/MLA NICE recommendation for CBT in menopause
According to NICE NG23, menopause-specific CBT is recommended for:
A. VMS only
B. VMS, sleep difficulties, and low mood
C. Osteoporosis prevention
D. Urogenital symptoms
Answer: B. NICE NG23 recommends menopause-specific CBT for VMS, sleep difficulties, and low mood.
MRCGP CBT alongside HRT
A patient on adequate HRT has good VMS control but significant ongoing anxiety. How should CBT be positioned?
A. CBT is unnecessary if HRT is prescribed
B. CBT can be offered alongside HRT for residual mood and anxiety symptoms
C. She should stop HRT and switch to CBT
D. CBT is only for women who cannot take HRT
Answer: B. CBT can be offered alongside HRT. NICE NG23 recommends it 'in addition to' HRT as well as instead of.
Professor Evidence quality for CBT in menopause
Evaluate the methodological challenges of conducting RCTs of CBT for menopause symptoms, particularly in relation to blinding and control conditions.
A. CBT trials are methodologically identical to drug trials
B. CBT trials face inherent challenges: participants cannot be blinded; control conditions (waitlist, usual care) may overestimate effect sizes; active controls (attention-matched sham) are difficult to design; outcomes rely on self-report measures susceptible to demand characteristics
C. All CBT evidence comes from uncontrolled case series
D. Blinding is straightforward in CBT research
Answer: B. The key challenge is absence of double-blinding: participants know they are receiving CBT. Waitlist controls overestimate effect sizes compared with active controls. The MsFLASH trials used attention-matched telephone controls, which improved rigour. Self-reported VMS reduction may reflect changed perception rather than physiological change (hence 'impact' rather than 'frequency' as outcome). Despite these limitations, the consistency of findings across multiple trials supports CBT as a genuinely effective intervention.
Take-Away Messages
- NICE NG23 recommends menopause-specific CBT for VMS, sleep, and low mood
- CBT reduces the IMPACT of VMS on quality of life, not necessarily their frequency
- CBT can be offered alongside HRT, instead of HRT, or when HRT is contraindicated
- CBT-I is first-line for chronic insomnia including menopause-related
- Access remains limited — guided self-help workbooks and online platforms are practical alternatives